Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Eli Lilly and Company
The Lymphoma Academic Research Organisation
National Cancer Centre, Singapore
Eli Lilly and Company
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Progen Pharmaceuticals
National Cancer Institute (NCI)
Teva Branded Pharmaceutical Products R&D, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)